Parkinson's disease biomarker and application thereof

A technology for biomarkers and Parkinson's disease, applied in the direction of microbial measurement/testing, biochemical equipment and methods, etc., can solve the problems of high subjectivity, low reliability, high cost, etc., and achieve the effect of low cost

Inactive Publication Date: 2020-05-22
XIAMEN UNIV
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the clinical diagnosis of PD mainly relies on the comprehensive evaluation of medical history, symptoms, signs, and imaging, but these methods have the disadvantages of high subjectivity, low reliability, and high cost.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Parkinson's disease biomarker and application thereof
  • Parkinson's disease biomarker and application thereof
  • Parkinson's disease biomarker and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Human peripheral blood circ-AMOTL1 expression detection

[0031] 1. Human blood sample collection

[0032] 10 peripheral blood samples of PD (Parkinson's disease) patients and 10 peripheral blood samples of normal people were collected.

[0033] Blood sample RNA extraction, reverse transcription and fluorescent quantitative PCR

[0034] (1) RNA extraction: According to the instructions, use the blood RNA extraction kit from TAKARA to extract RNA from blood samples. 2 μl was taken from the final RNA for quantification.

[0035] (2) Reverse transcription: according to the instructions, use the reverse transcription kit from MedChemExpress Company:

[0036] reaction system:

[0037] 2×Super RT Mix 10μL

[0038] Total RNA 1μg

[0039] RNase-Free H2O To 20μL

[0040] Reaction conditions:

[0041] Step 1: 10 minutes at 25°C;

[0042] Step 2: 45 minutes at 42°C;

[0043] The third step: 85°C for 2 minutes.

[0044] (3) Fluorescence quantitative PCR: accord...

Embodiment 2

[0056] Example 2 Detection of Circ-AMOTL1 expression in peripheral blood of mice and counting of dopaminergic neurons

[0057] 1. Model establishment

[0058]This protocol uses internationally commonly used PD mouse models: 32 10-week-old male C57BL mice were randomly divided into four groups, PD 1-day group, PD 7-day group, control 1-day group, and control 7-day group. The mice in the PD 1-day group and the PD 7-day group were intraperitoneally injected with 1-methyl-4-phenyl-1,2,4,5-tetrahydropyridine (MPTP) at a dose of 30 mg / kg for 5 consecutive days. The 1-day group and the control 7-day group were injected with the same dose of normal saline.

[0059] 2. Mouse sample collection

[0060] On day 1 after the last injection, blood and midbrain tissue samples were taken from mice in PD 1-day group and control 1-day group after anesthesia, or were perfused and fixed sequentially with normal saline and 4% paraformaldehyde through the aorta, Open the skull and take whole brai...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a Parkinson's disease biomarker and application thereof. The invention provides the biomarker for Parkinson's disease. The biomarker is circular RNA. The circular RNA is circ-AMOTL1, and the circ-AMOTL1 is a nucleotide sequence as shown in SEQ ID NO:1. The invention provides a method for early diagnosis of Parkinson's disease or related diseases and prediction of disease risk, and can solve the disadvantages that existing Parkinson's disease diagnosis methods cannot realize early warning and cannot predict Parkinson's disease.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a Parkinson's disease biomarker and its application. Background technique [0002] Parkinson's disease (PD) is a common degenerative disease of the central nervous system. Symptoms such as posture and gait disorders seriously affect the health and quality of life of patients, and bring a heavy burden to patients, their families and society. At present, the clinical diagnosis of PD mainly relies on the comprehensive evaluation of medical history, symptoms, signs, and imaging studies, but these methods have the disadvantages of high subjectivity, low reliability, and high cost. In addition, early intervention can significantly improve the quality of life and prolong the survival time of PD patients. However, when the patient has already shown symptoms and signs, most of the dopaminergic neurons have been lost, and the opportunity for early intervention has been missed. [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883
CPCC12Q1/6883C12Q2600/158C12Q2600/178
Inventor 王翀李娟
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap